anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Prepn. of porous silica gel powder of low density comprises: (a) adding an acid soln. to a basic aq. silicate soln. to cause neutralisation; (b) forming a hydrosol from the above reaction mixt.; (c) gelling the hydrosol to give a hydrogel and then destroying this to give a silica gel slurry; (d) sepg., washing, drying and decomposing the hydrogel slurry. In step (a) mixing the solns. is carried out by spraying, in order to achieve partial neutralisation of the reaction mixt. at pH 11.6 or more, and then further adding acid soln. to give a reaction mixt. of pH 10.8-11.4.
Disclosed is a method that is based on a conventional perfume oil. For example, 7 parts of a solubilizer are homogeneously mixed with 2.5 to 3.5 parts of Hydrolite-5, whereupon 3 parts of perfume oil are added and mixed until a homogeneous, clear solution is obtained. Eighty parts are then deionized and are blown with nitrogen. Said preprocessed water is slowly added while being stirred vigorously. The final mixture is blown with nitrogen. The inventive perfume is composed of a solubilizer, Hydrolite-5, a perfume oil, and deionized water that is blown with nitrogen. Said perfume is less expensive to produce, stable, gentle to the skin, not subject to VOC taxes, and takes a long time to lose its fragrance.
Patients receive doxorubicin hydrochloride IV over 5-10 minutes and alvocidib IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients reaching a cumulative doxorubicin dose of 600 mg/m\^2 or experiencing cardiotoxicity may receive alvocidib alone at the discretion of the investigator. Cohorts of 3-6 patients receive escalating doses of alvocidib until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Ten additional patients receive treatment at the MTD. Patients are followed every 3 months for 1 year.
A method for administering a medicament suitable for treating a migraine or cluster headache to a patient in need thereof includes placing a mounting surface of a fluid delivery apparatus with the medicament in contact with at least a portion of the skin of said patient. A flow rate of the medicament from the fluid delivery apparatus is adjusted such that the medicament is delivered to the patient for at least a predetermined time period. The fluid delivery apparatus includes a controller assembly having a body component defining an axis and a plunger component slidably coupled to the body component. The plunger is positionable between a first position in which the plunger is nearest to the body component and a second position in which the plunger component is furthest from the body component. A bias assembly is positioned between the body component and the plunger component. The bias assembly is configured to apply a two stage force profile to the plunger component. Also disclosed is a method for administering sumatriptan to a patient in need thereof such that the Cmax, Tmax and AUC are within predetermined, therapeutically effective values.
In breast cancer, increased neutrophil levels and decreased lymphocyte levels in peripheral blood are associated with worse overall survival (OS). In HR+, HER2- metastatic breast cancers, low pretreatment NLR and high pretreatment absolute lymphocyte count (ALC) were related with better progression-free survival (PFS) and OS. The development of predictive models, based on machine learning (ML) algorithms it has been used in prognostication and assist in the diagnosis of different types of cancer.

Although regular laboratory tests have potential to be breast cancer biomarkers, a single test is yet to provide adequate sensitivity or specificity. Artificial intelligence (AI) could help with integrating data from multiple tests to aid diagnosis. Technical improvements such as data storage capacity, computing power, and better algorithms mean that ML can process clinically meaningful information from laboratory test data. Models' generalisability and stability still need to be confirmed, in view of limitations such as the absence of various pathological types, small cohorts, and lack of external validation. Therefore, a competitive model is also essential to achieve more accurate stratification of patients with breast cancer. The purpose of this retrospective multicentre study is to systematically evaluate the ability of laboratory tests to predict breast cancer, and develop a robust and generalisable model to assist in identifying patients with breast cancer.
Group I: i.V. paracetamol 1 g (100 ml) was given 30 min before induction of anesthesia.
BACKGROUND: Type 2 myocardial infarction (MI) is becoming more recognized. This study aimed to assess the factors linked to type 2 MI in older adults with pneumonia and further determine the predictive factors of 90-day adverse events (refractory heart failure, cardiogenic shock, and all-cause mortality).
METHODS: A single-center retrospective analysis was conducted among older adults with pneumonia. The primary outcome was the prevalence of type 2 MI. The secondary objective was to assess the adverse events in these patients with type 2 MI within 90 days.
RESULTS: A total of 2618 patients were included. Of these, 361 patients (13.8%) suffered from type 2 MI. Multivariable predictors of type 2 MI were chronic kidney disease (CKD), age-adjusted Charlson comorbidity index (ACCI) score, and NT-proBNP > 4165pg/mL. Moreover, the independent predictive factors of 90-day adverse events included NT-proBNP > 4165pg/mL, age, ACCI score, and CKD. The Kaplan-Meier adverse events curves revealed that the type 2 MI patients with CKD and NT-proBNP > 4165pg/mL had a higher risk than CKD or NT-proBNP > 4165pg/mL alone.
CONCLUSION: Type 2 MI in older pneumonia hospitalization represents a heterogeneous population. Elevated NT-proBNP level and prevalence of CKD are important predictors of type 2 MI and 90-day adverse events in type 2 MI patients.
To ensure that the benefits of opioid analgesics outweigh the risks of addiction, abuse, and misuse, the Food and Drug Administration (FDA) has required a Risk Evaluation and Mitigation Strategy (REMS) for these products. Under the requirements of the REMS, drug companies with approved opioid analgesic products must make REMS-compliant education programs available to healthcare providers. Healthcare providers are strongly encouraged to do all of the following: 

    Complete a Error! Hyperlink reference not valid. offered by an accredited provider of continuing education (CE) or another education program that includes all the elements of the FDA Education Blueprint for Health Care Providers Involved in the Management or Support of Patients with Pain.
    Discuss the safe use, serious risks, and proper storage and disposal of opioid analgesics with patients and/or their caregivers every time these medicines are prescribed. The Patient Counseling Guide (PCG) can be obtained at this link: Error! Hyperlink reference not valid..
    Emphasize to patients and their caregivers the importance of reading the Medication Guide that they will receive from their pharmacist every time an opioid analgesic is dispensed to them.
    Consider using other tools to improve patient, household, and community safety, such as patient-prescriber agreements that reinforce patient-prescriber responsibilities.

To obtain further information on the opioid analgesic REMS and for a list of accredited REMS CME/CE, call 1-800-503-0784, or log on to Error! Hyperlink reference not valid.. The FDA Blueprint can be found at Error! Hyperlink reference not valid..
INTRODUCTION: Microwave ablation (MWA) effectively treats adenomyosis, yet symptom recurrence remains challenging. Thus, our study aims to explore the independent risk factors related to symptom recurrence after MWA of symptomatic adenomyosis.
MATERIAL AND METHODS: Patients with symptomatic adenomyosis who received MWA treatment at our institute from June 2020 to June 2023 were retrospectively included. Preoperative and intraoperative clinical data were retrospectively collected, and symptom relief following MWA was systematically monitored. Independent risk factors for symptom recurrence after MWA of adenomyosis were explored through Cox regression analysis. Kaplan-Meier (K-M) curves were plotted to estimate recurrence-free survival, and differences between groups were analyzed using the Log-Rank test.
RESULT: In total, 38 patients with adenomyosis were included, with a median follow-up duration of 15 months (interquartile range: 10-23 months). Among them, 81.58% (31/38) of patients experienced significant symptom relief, while 18.42% (7/38) reported partial relief, culminating in a clinical success rate of 100%. The symptom recurrence rate was 21.05% (8/38). Multivariate COX proportional hazards regression indicated that the fertility requirement, the absence of artificial ascites during the MWA procedure, and inadequate EPV (<524 J/cm3) were independent risk factors for symptom recurrence after MWA of adenomyosis.
CONCLUSION: MWA is an effective treatment for relieving symptoms of adenomyosis. While fertility requirements, without artificial ascites assistance, and lower EPV were independent risk factors for symptom recurrence after MWA of adenomyosis.
Vascular implant decision support uses medical imaging systems. A physics-based model of an endovascular implant is used to simulate deployment of a vascular model of a patient based on medical imaging. The porosity of the deployed implant and the simulation are used to determine a value for each of one or more hemodynamic parameters to support decisions for intravascular treatment. The machine learning network uses patient-specific information to select endovascular implants, placements, and/or other implant configurations for simulating deployment and/or predicting outcome from patient deployment. The clinician may use decision support to select among options for implantation and/or to confirm the sufficiency of the plan. Various of these methods may be used alone or in combination.
A randomized, double-blind, multicenter study (BOLERO-2, NCT00863655) of everolimus tablets in combination with exemestane vs. placebo in combination with exemestane was conducted in 724 postmenopausal women with estrogen receptor-positive, HER2-negative advanced breast cancer with recurrence or progression following prior therapy with letrozole or anastrozole. Randomization was stratified by documented sensitivity to prior hormonal therapy (yes vs. no) and by the presence of visceral metastasis (yes vs. no). Sensitivity to prior hormonal therapy was defined as either (1) documented clinical benefit (complete response [CR], partial response [PR], stable disease ≥ 24 weeks) to at least one prior hormonal therapy in the advanced setting or (2) at least 24 months of adjuvant hormonal therapy prior to recurrence. Patients were permitted to have received 0-1 prior lines of chemotherapy for advanced disease. The major efficacy outcome measure was progression-free survival (PFS) evaluated by RECIST (Response Evaluation Criteria in Solid Tumors), based on investigator (local radiology) assessment. Other outcome measures included overall survival (OS) and objective response rate (ORR).

Patients were randomized 2:1 to everolimus tablets 10 mg orally once daily in combination with exemestane 25 mg once daily (n = 485) or to placebo in combination with exemestane 25 mg orally once daily (n = 239). The two treatment groups were generally balanced with respect to baseline demographics and disease characteristics. Patients were not permitted to cross over to everolimus tablets at the time of disease progression.

The trial demonstrated a statistically significant improvement in PFS by investigator assessment (Table 20 and Figure 1). The results of the PFS analysis based on independent central radiological assessment were consistent with the investigator assessment. PFS results were also consistent across the subgroups of age, race, presence and extent of visceral metastases, and sensitivity to prior hormonal therapy.

ORR was higher in the everolimus tablets in combination with exemestane arm vs. the placebo in combination with exemestane arm (Table 20). There were 3 complete responses (0.6%) and 58 partial responses (12%) in the everolimus tablets arm. There were no complete responses and 4 partial responses (1.7%) in the placebo in combination with exemestane arm.

After a median follow-up of 39.3 months, there was no statistically significant difference in OS between the everolimus tablets in combination with exemestane arm and the placebo in combination with exemestane arm [HR 0.89 (95% CI: 0.73, 1.10)].

Figure 1: Kaplan-Meier Curves for Progression-Free Survival by Investigator Radiological Review in Hormone Receptor-Positive, HER-2 Negative Breast Cancer in BOLERO-2
Example embodiments disclosed herein relate to methods and systems for determining whether particular actions affect or influence medical symptoms of patients. In one example, a plurality of datasets from a corresponding plurality of patients is received, where each patient has a corresponding disease. An individual dataset for an individual patient may include information about at least one disease symptom of the patient and at least one action of the patient. After the datasets are received from the patients, the datasets are stored in a database. Using the datasets stored in the database, a correlation between one or more actions and one or more disease symptoms may be determined based on a statistical analysis of the actions and symptoms stored in the database. The correlation between the one or more actions and the one or more disease symptoms may also be stored in the database.
Participants will be provided food for lunch and dinner with 360mL apple juice which was stored in PVC blood bag for 24 hours in 4 ℃. After 1 week, participant will cross over to other intervention.
Cases of drug-induced liver injury (DILI) have been observed with ESBRIET. In the postmarketing period, non-serious and serious cases of DILI, including severe liver injury with fatal outcome, have been reported. Patients treated with Esbriet 2403 mg/day in three Phase 3 trials had a higher incidence of elevations in ALT or AST ≥3× ULN than placebo patients (3.7% vs 0.8%, respectively). Elevations ≥10×ULN in ALT or AST occurred in 0.3% of patients in the Esbriet 2403 mg/day group and in 0.2% of patients in the placebo group. Increases in ALT and AST ≥3× ULN were reversible with dose modification or treatment discontinuation.

Conduct liver function tests (ALT, AST, and bilirubin) prior to the initiation of therapy with ESBRIET, monthly for the first 6 months, every 3 months thereafter, and as clinically indicated. Measure liver function tests promptly in patients who report symptoms that may indicate liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine, or jaundice. Dosage modification or interruption may be necessary for liver enzyme elevations [see Dosage and Administration (2.1, 2.3)].
To provide an oral solid preparation excellent in light stability in which decomposition of silodosin due to light is inhibited.SOLUTION: The present invention relates to an oral solid preparation, such as an orally disintegrating tablet, which separately contains each of a photostabilizer and a granular drug that contains silodosin. Preferably, the photostabilizer is selected from the group consisting of titanium oxide, yellow iron oxide, yellow iron sesquioxide, brown iron oxide, iron sesquioxide, Food Yellow No. 4, Food Yellow No. 5, Food Yellow No. 4, aluminum lake, Food Red No. 2, Food Red No. 3 and Food Red No. 102.SELECTED DRAWING: None
STUDY OBJECTIVES: Napping is a common habit in many countries. Nevertheless, studies about the chronic effects of napping on obesity are contradictory, and the molecular link between napping and metabolic alterations has yet to be studied. We aim to identify molecular mechanisms in adipose tissue (AT) that may connect napping and abdominal obesity.
METHODS: In this cross-sectional study, we extracted the RNA repeatedly across 24 hours from cultured AT explants and performed RNA sequencing. Circadian rhythms were analyzed using six consecutive time points across 24 hours. We also assessed global gene expression in each group (nappers vs. non-nappers).
RESULTS: With napping, there was an 88% decrease in the number of rhythmic genes compared to that in non-nappers, a reduction in rhythm amplitudes of 29%, and significant phase changes from a coherent unimodal acrophase in non-nappers, towards a scattered and bimodal acrophase in nappers. Those genes that lost rhythmicity with napping were mainly involved in pathways of glucose and lipid metabolism, and of the circadian clock. Additionally, we found differential global gene expression between nappers and non-nappers with 34 genes down- and 32 genes upregulated in nappers. The top upregulated gene (IER3) and top down-regulated pseudogene (VDAC2P2) in nappers have been previously shown to be involved in inflammation.
CONCLUSIONS: These new findings have implications for our understanding of napping's relationship with obesity and metabolic disorders.
The invention provides a humanized anti-human epidermal growth factor receptor (EGFR) antibody and an application thereof. Through humanization on an EGFR mouse monoclonal antibody LA22, humanized amino acid sequences accounts for more than 90% in the antibody LA22 and then an anti-human EGFR monoclonal antibody is screened. An affinity between the antibody in the invention and human EGFR is 2.3 nM and is similar to that between a mouse antibody and the human EGFR. When combined with EGFRs on surfaces of tumor cells, the antibody can induce the EGFRs on the surfaces of the tumor cells to be endocytosed and becomes a very ideal biological targeted therapy antibody. The invention aims at prevention and treatment of tumors targeted by EGFR and other diseases, such as inflammation and autoimmune diseases, and provides a specific antibody medicine. A risk that the antibody medicine will generate human anti-mouse antibody (HAMA) in a patient body in future can be significantly reduced. The antibody medicine is prolonged in a half-life period and is improved in curative effects.
ZOLADEX is contraindicated during pregnancy unless ZOLADEX is being used for palliative treatment of advanced breast cancer. There are no adequate and well-controlled studies in pregnant women using ZOLADEX. Based on mechanism of action in humans and findings of increased pregnancy loss in animal studies, ZOLADEX can cause fetal harm when administered to a pregnant woman. If this drug is used during pregnancy, the patient should be apprised of the potential hazard to the fetus. There is an increased risk for pregnancy loss due to expected hormone changes that occur with ZOLADEX treatment. 

ZOLADEX crosses the placenta in rats and rabbits following subcutaneous administration. Administration of goserelin to pregnant rats and rabbits during organogenesis resulted in increased preimplantation loss and increased resorptions. When pregnant rats received goserelin throughout gestation and lactation, there was a dose-related increase in umbilical hernia in offspring. In additional reproduction studies in rats, goserelin decreased fetus and pup survival. Human dose/exposure multiples could not be calculated from available animal data. 

Actual animal doses: rat (≥ 2 mcg/kg/day for pregnancy loss; > 10 mcg/kg/day for umbilical hernia in offspring); rabbits (> 20 mcg/kg/day).
Bronchiectasis is characterized by pathological and irreversible dilation of bronchi caused by the inefficient removal of secretions and microorganisms and the perpetuation of inflammatory processes induced by chronic or recurrent infections, causing more damage to the airways that result in infections, and greater lesion airways and lung parenchyma. Pulmonary rehabilitation in people with bronchiectasis aims to improve exercise capacity, through effects on aerobic capacity and peripheral muscles, and to improve disease control and quality of life. The aim this study is to evaluate the effects of pulmonary rehabilitation on the transport of secretions, inflammation and respiratory resistance, and its repercussions on the quality of life in patients with bronchiectasis. In this study 60 volunteers, of both sexes, aged between 18-60 years, adequate the inclusion criteria, which will be assessed by lung function tests, the saccharin transport time, the inflammatory markers in the airways, the respiratory system resistance and quality of life scales. Volunteers will be randomly divided in pulmonary rehabilitation (PRG) and control groups (CG) that will be subdivided in bronchiectasis and healthy subgroups. In the PRG group they will receive supervised physical training twice a week and will be instructed to adopt a routine of home exercises, while CG will be informed about the benefits of physical activities. All volunteers will be evaluated after 8 weeks of the baseline and at the end of the research. Data evolution will be collected from medical records and notes of the medical team and physical therapy that will follow the routine of these participants
Subjects with major depressive disorder (MDD) who are scheduled to receive ketamine infusions will complete the video task and imaginal task twice. The first visit will be before any ketamine treatment. The second visit will be within 1 week after first ketamine infusion. This is NOT at treatment study. Study inclusion is open to participants with MDD who are already planning to receive ketamine treatment at Emory. No treatment is offered through this study.
Treatment duration was a mean of 4 weeks. Therapy was performed daily excluding weekends and consisted of 45 minutes of individual work with an oncological physiotherapist. The control group underwent kinesiotherapeutic procedures that included various floor gymnastic exercises with gymnastic stick, balls, and/or elastic tapes, conventional massage of neck and shoulder girdle muscles and therapeutic exercises to increase ROM in the upper limb and in the chest area. Before or after every of the treatment procedure control group patients underwent ten-minute manual lymphatic drainage in the limb on the mastectomy side.
<P>PROBLEM TO BE SOLVED: To provide a galenical composition for enhancing an anticancer/immune/ hematopoietic function and protecting a human body from an oxidative damage.  <P>SOLUTION: The galenical composition composed of hot-water extracts of Angelicae Radix, Cnidii Rhizoma, and Paeonia albiflora mixed in the same weight ratio and a polysaccharide fraction of a precipitate formed by adding ethanol to the hot-water extracts of Angelicae Radix, Cnidii Rhizoma, and Paeonia albiflora mixed in the same weight ratio is provided. The galenical composition exhibits the excellent anticancer/immune/hematopoietic function enhancing effect and the oxidative living body damage suppressing effect. The composition is applied to the prevention of the side effect of the anti-tumor therapy through the recovery promotion from an immune/hematopoietic function disorder and the suppression of oxidative damage caused by an anticancer agent treatment and radiotherapy treatment. The composition is widely used to the prevention of various regressive chronic diseases and the health promotion of an aged weak person.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
1,236,707. Enzyme preparations. STE. DE RECHERCHES INDUSTRIELLES S.O.R.I. 16 May, 1969 [31 Oct., 1968], No. 24964/69. Heading A5B. [Also in Divisions C3 and C4] A process for the stabilisation of an enzymatic powder medicament in an aerosol container comprises mixing the enzymatic powder with an excipient consisting of a polyalcohol and placing the mixture in an aerosol container together with an inert propellant. The enzyme may be a protease, decarboxylase, catalase, or hyaluromidase; the excipient may be lactose, and may include magnesium stearate; the propellant may be a mixture of chlorofluorinated hydrocarbons.